Clinical trial
A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
NCT00857545 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission
- Lead sponsor
- Gynecologic Oncology Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2010
- Completion date
- Not reported
- Enrollment
- 171 (actual)
- Sites
- 46
Conditions
As the registry lists them; a condition with its own page is linked.
stage ia fallopian tube cancer, stage ia ovarian cancer, stage ib fallopian tube cancer, stage ib ovarian cancer, stage ic fallopian tube cancer, stage ic ovarian cancer, stage iia fallopian tube cancer, stage iia ovarian cancer, stage iib fallopian tube cancer, stage iib ovarian cancer, stage iic fallopian tube cancer, stage iic ovarian cancer, stage iiia fallopian tube cancer, stage iiia ovarian cancer, stage iiia primary peritoneal cancer, stage iiib fallopian tube cancer, stage iiib ovarian cancer, stage iiib primary peritoneal cancer, stage iiic fallopian tube cancer, stage iiic ovarian cancer, stage iiic primary peritoneal cancer, stage iv fallopian tube cancer, stage iv ovarian cancer, stage iv primary peritoneal cancer